Literature DB >> 14711930

Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.

Ichiro Takasaki1, Tomohiko Suzuki, Atsushi Sasaki, Kaoru Nakao, Mikito Hirakata, Kiyoshi Okano, Toshiaki Tanaka, Hiroshi Nagase, Kimiyasu Shiraki, Hiroshi Nojima, Yasushi Kuraishi.   

Abstract

(-)-17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[N-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) is a kappa-opioid receptor agonist that has pharmacological characteristics different from typical kappa-opioid receptor agonists. This study was conducted to determine the antiallodynic and antihyperalgesic effects of TRK-820 in a mouse model of acute herpetic pain and to compare them with those of the kappa-opioid receptor agonist enadoline and the mu-opioid receptor agonist morphine. Percutaneous inoculation with herpes simplex virus type-1 induced tactile allodynia and mechanical hyperalgesia in the hind paw on the inoculated side. TRK-820 (0.01-0.1 mg/kg p.o.), enadoline (1-10 mg/kg p.o.) and morphine (5-20 mg/kg p.o.) dose dependently inhibited the allodynia and hyperalgesia, but the antiallodynic and antihyperalgesic dose of enadoline markedly decreased spontaneous locomotor activity. The antinociceptive action of TRK-820 (0.1 mg/kg) was completely antagonized by pretreatment with norbinaltorphimine, a kappa-opioid receptor antagonist, but not by naltrexone, a mu-opioid receptor antagonist. Repeated treatment with morphine (20 mg/kg, four times) resulted in the reduction of antiallodynic and antihyperalgesic effects, whereas the inhibitory potency of TRK-820 (0.1 mg/kg) was almost the same even after the fourth administration. There was no cross-tolerance in antinociceptive activities between TRK-820 and morphine. Intrathecal and intracerebroventricular, but not intraplantar, injections of TRK-820 (10-100 ng/site) suppressed the allodynia and hyperalgesia. These results suggest that TRK-820 inhibits acute herpetic pain through kappa-opioid receptors in the spinal and supraspinal levels. TRK-820 may have clinical efficacy in acute herpetic pain with enough safety margins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711930     DOI: 10.1124/jpet.103.059816

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.

Authors:  Selena S Schattauer; Jamie R Kuhar; Allisa Song; Charles Chavkin
Journal:  Cell Signal       Date:  2017-01-11       Impact factor: 4.315

2.  Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.

Authors:  Yan Zhou; Kevin Freeman; Vincent Setola; Danni Cao; Shane Kaski; Mary Jeanne Kreek; Lee-Yuan Liu-Chen
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Modeling genetic imprinting effects of DNA sequences with multilocus polymorphism data.

Authors:  Sheron Wen; Chenguang Wang; Arthur Berg; Yao Li; Myron M Chang; Roger B Fillingim; Margaret R Wallace; Roland Staud; Lee Kaplan; Rongling Wu
Journal:  Algorithms Mol Biol       Date:  2009-08-11       Impact factor: 1.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.